Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 157 - 168 of 433
General Hepatology
EASL Studio Podcast S4 E21: Why you should stop smoking if you love your liver

EASL Studio Podcast S4 E21: Why you should stop smoking if you love your liver

Podcasts
View
Metabolism, Alcohol & Toxicity
Quiz: A quarter of the global adult population is estimated to have non-alcoholic fatty liver disease (NAFLD)

Quiz: A quarter of the global adult population is estimated to have non-alcoholic fatty liver disease (NAFLD)

Quiz
View

EASL Studio S4 E20: COST Actions: Opportunities for pan-European collaborations in liver diseases

Description

Collaborations are key in achieving scientific progress. The European Horizon COST Actions provide great opportunities to build, grant, and/or participate in pan-European collaborations in multidisciplinary topics, including liver diseases.

This EASL Studio:

  • Provides you with information about the COST Action programme.
  • Discusses the structure of the drug-induced liver injury (DILI) and cholangiocarcinoma (CCA) working groups.
  • Highlights the potential for collaborative work within this programme.

Faculty

  • Prof. Jesús Bañales (Moderator)
  • Prof. Raul Andrade (Faculty)
  • Dr Chiara Braconi (Faculty)
  • Prof. Vincenzo Cardinale (Faculty)

Related episodes

  • S4E13: EASL-EF CLIF and EU Grants: Exploring novel mechanisms and treatment of chronic liver failure
  • S4E2: YI Choice: How to build consortia and registries

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

 

Log in to post comments
General Hepatology
EASL Studio Podcast S4 E20: COST Actions: Opportunities for pan-European collaborations in liver diseases

EASL Studio Podcast S4 E20: COST Actions: Opportunities for pan-European collaborations in liver diseases

Podcasts
View
General Hepatology
EASL Studio Podcast S4 Special Edition: Promoting Liver Health: An urgent call for action at WHO

EASL Studio Podcast S4 Special Edition: Promoting Liver Health: An urgent call for action at WHO

Podcasts
View

EASL Studio S4 Special Edition: Promoting Liver Health: An urgent call for action at WHO

Description

On 22 May 2023, policymakers, thought leaders, Permanent Mission Representatives to the UN, WHO staff, and people affected by liver disease will gather at the EASL Office in Geneva for the invitation-only event on the side-lines of the 76th World Health Assembly*: “Together for Better Liver Health: Mobilising Action for Fatty Liver Disease”. The aim of the event is to raise awareness on the need for action, and to call for a coordinated response to combat the global public health threat represented by fatty liver disease.

Fatty liver disease is the most prevalent liver disease in history, affecting over one in three adults globally and 10% of children. If left unchecked, it can progress to cirrhosis and liver cancer. Despite its prevalence, fatty liver disease remains largely unknown, and its burden is expected to grow further in the years ahead.

The episode showcases the collective effort of global stakeholders who stand united to advocate that fatty liver diseases are included in national and global policies. Our moderator, EASL Vice-Secretary Prof. Aleksander Krag, is joined by distinguished faculty members representing organisations from around the world.

Don’t miss this opportunity to learn about the strategies being put in place to promote liver health and the urgent need for coordinated approaches. Participate in this call for action to address fatty liver disease as a critical step toward a healthier future for all.

*The World Health Assembly is held annually and is an occasion for all WHO member delegations to discuss and make strides on global health issues. The EASL event builds upon WHA76 agenda item 11.2 which includes discussions on policy options and cost-effective interventions for the prevention and control of noncommunicable disease (NCDs). By raising the profile of fatty liver disease, the EASL’s event on the side-lines of the WHA and the publicly accessible EASL Studio special episode can help to catalyse action and improve liver health outcomes worldwide.

Faculty

  • Prof. Aleksander Krag (Moderator)
  • Prof. Ajay Duseja (Faculty)
  • Prof. Manal El-Sayed (Faculty)
  • Mr. Marko Korenjak (Faculty)
  • Prof. Mario Pessoa (Faculty)
  • Prof. Mary E. Rinella (Faculty)

This EASL Studio has been sponsored by Boehringer Ingelheim and Novo Nordisk. The sponsors have had no editorial control over the content featured.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

 

Log in to post comments
Basic Science
Quiz: Concerning newly developed patient-derived xenograft models of cholangiocarcinoma

Quiz: Concerning newly developed patient-derived xenograft models of cholangiocarcinoma

Quiz
View

EASL Studio S4 E19: HDV: The devil becomes treatable

Description

Hepatitis D is the most severe form of viral hepatitis infection, but fortunately, new treatments are on the horizon.

This EASL Studio discusses:

  • Which patients should be treated.
  • Currently available treatment options.
  • Treatment combinations and duration.
  • New treatments in development.

Faculty

  • Prof. Heiner Wedemeyer (Moderator)
  • Prof. Soo Aleman (Faculty)
  • Prof. Pietro Lampertico (Faculty)

Related episodes:

  • S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor.
  • S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition.
  • Midday Talks: HBV and HDV drug development – Where do we stand and where are we going?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

 

Log in to post comments
Viral Hepatitis
EASL Studio Podcast S4 E19: HDV: The devil becomes treatable

EASL Studio Podcast S4 E19: HDV: The devil becomes treatable

Podcasts
View

EASL Studio S2 E17: EASL Haemochromatosis Guidelines 2022

Description

In honour of World Haemochromatosis week (1-7 June 2022) the newly updated EASL Clinical Practice Guidelines on Haemochromatosis were discussed in this episode of EASL Studio.

Read more

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

 

Moderator

 
Heinz Zoller

Heinz Zoller is Professor of Hepatology at the Medical University of Innsbruck and Research Director at the Christian-Doppler Laboratory on Iron and Phosphate Biology. His clinical responsibilities include the care for patients in General- and Transplant-Hepatology at the Innsbruck University Hospital. His main academic focus is on genetic liver diseases, mainly hemochromatosis. He and his team aim at delivering and improving patient care through continuous education & training as well as basic scientific research & clinical studies.

Faculty

 
Elena Corradini Elena Corradini is Associate Professor of Internal Medicine at the University of Modena and Reggio Emilia, Italy. She is the referring physician for the Hemochromatosis and Hereditary Liver Diseases outpatient Clinic and Laboratory of Molecular Genetics at the University of Modena. She is also a member of the Iron Metabolism laboratory led by prof. A. Pietrangelo. Her basic and clinical research activities focus primarily on iron metabolism and iron-related disorders, including genetic and acquired liver diseases with altered iron homeostasis, and complex internal medicine diseases.
John Ryan

Dr John Ryan is a Consultant Hepatologist and Associate Clinical Professor at the Hepatology Unit, Beaumont Hospital and RCSI University of Medicine, Dublin. His clinical and research interests include iron metabolism, alcohol and chronic liver disease.

Log in to post comments
General Hepatology
Quiz: A portal vein thrombosis (PVT) is diagnosed in a 50 years-old man with polycythaemia vera.

Quiz: A portal vein thrombosis (PVT) is diagnosed in a 50 years-old man with polycythaemia vera.

Quiz
View
General Hepatology
EASL Studio Podcast S4 E18: Liver nurses in Europe: Are there enough and can they do more?

EASL Studio Podcast S4 E18: Liver nurses in Europe: Are there enough and can they do more?

Podcasts
View